PLOS is a non-profit organization on a mission to drive open science forward with measurable, meaningful change in research publishing, policy, and practice.

Building on a strong legacy of pioneering innovation, PLOS continues to be a catalyst, reimagining models to meet open science principles, removing barriers and promoting inclusion in knowledge creation and sharing, and publishing research outputs that enable everyone to learn from, reuse and build upon scientific knowledge.

We believe in a better future where science is open to all, for all.

Journals
More Content
PLOS BLOGS Speaking of Medicine and Health
Browse all PLOS Blogs
Browse all PLOS Blogs

This Week in PLoS Medicine: WHO’s PMTCT; WTO compulsory licenses; & more

Michael Morris General

Image Credit: e-Magine Art

Four new articles were published in PLoS Medicine this week:

Using a simulation model, Andrea Ciaranello and colleagues find that the latest WHO PMTCT guidelines plus better access to PMTCT programs, better retention of women in care, and better adherence to drugs are needed to eliminate pediatric HIV in Zimbabwe.

Reed Beall and Randall Kuhn describe their analysis of the use of compulsory licenses for pharmaceutical products by World Trade Organization members since 1995.

Linda Flinterman and colleagues report on the long-term mortality rate for individuals who have experienced a first venous thrombosis or pulmonary embolism, describing an ongoing elevated risk of death compared to controls for up to eight years after the event.

Jason Nickerson and Amir Attaran examine the vast inequities in medical pain relief around the world and argue that the global control of licit narcotics be shifted from the International Narcotic Control Board to WHO.

Remember you can comment on, annotate and rate any PLoS Medicine article and see the views, citations and other indications of impact of an article on that articles metrics tab.

Back to top